You can buy or sell CytomX and other stocks, options, and ETFs commission-free!
CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA. The listed name for CTMX is CytomX Therapeutics, Inc. Common Stock.
Sean A. McCarthy
South San Francisco, California
52 Week High
52 Week Low
— per share
Expected Feb 25, After Hours